BEST1 rs121908869: What Your Genotype Means
The genetic variant rs121908869 is a very rare missense mutation within the BEST1 gene, altering the encoded bestrophin-1 ion channel protein via an arginine-to-cysteine substitution (p.Arg218Cys). In ophthalmic genetics research, this missense change is associated with Best vitelliform macular dystrophy (BVMD), an inherited form of central retinal degeneration characterized by distinctive, egg-yolk-like lipofuscin deposits beneath the macula.
What each genotype means
Typical macular health risk
You carry two copies of the common reference allele at this position in the BEST1 gene. This genotype is not associated with Best vitelliform macular dystrophy or related bestrophinopathy disorders. Your genetic baseline for macular degeneration associated with this specific locus remains typical.
Carried by more than 99.99% of individuals across all major global populations.
Best vitelliform macular dystrophy risk
You carry one copy of the rare pathogenic T allele (encoding the p.Arg218Cys amino acid change) in the BEST1 gene. This variant is documented in clinical databases to cause Best vitelliform macular dystrophy via an autosomal dominant inheritance pattern, typically characterized by egg-yolk-like retinal lesions and progressive central vision loss. Clinical penetrance and symptom severity can vary considerably among heterozygous individuals.
Extremely rare; observed in fewer than 1 in 50,000 people globally according to gnomAD population data.
Severe bestrophinopathy risk
You carry two copies of the rare pathogenic T allele in the BEST1 gene. Biallelic alterations in BEST1 are associated with severe autosomal recessive or dominant bestrophinopathies, often causing early-onset retinal dystrophy and substantial visual impairment. Because this variant acts dominantly, carrying two altered copies is exceptionally uncommon and linked to pronounced macular pathology.
Extremely rare worldwide, with an expected frequency far below 1 in several million individuals.
What the Variant Is and Where It Sits
The variant designated rs121908869 resides within the BEST1 gene (historically known as VMD2), positioned on the long arm of human chromosome 11 at 11q12.3. At the genomic level, this change alters the standard nucleotide sequence within coding exon 6 of the BEST1 transcript (commonly referenced as c.652C>T). This nucleotide transition substitutes the basic, positively charged amino acid arginine with a neutral cysteine residue at position 218 (p.Arg218Cys) of the polypeptide chain. Because amino acid 218 lies within an essential, highly conserved intracellular domain adjacent to the channel's transmembrane architecture, replacing it with cysteine introduces a structural shift that alters how the channel subunits interact and respond to intracellular signals.
The Role of the BEST1 Gene and Bestrophin-1
The BEST1 gene encodes bestrophin-1, an integral transmembrane protein that functions as a homo-pentameric, calcium-activated chloride and bicarbonate ion channel. Bestrophin-1 is predominantly expressed within the basolateral membrane of the retinal pigment epithelium (RPE), a single layer of specialized cells that supports, nourishes, and maintains the overlying light-detecting photoreceptors in the eye. By facilitating the regulated exchange of chloride and fluid between the RPE and the subretinal space, bestrophin-1 maintains electrical resting potentials and normal fluid balance across the retina. When bestrophin-1 function is impaired, the metabolic clearance of shed photoreceptor outer segments falters, allowing yellow fluid and fluorophores (lipofuscin) to accumulate beneath the central retina.
Clinical Research and Evidence Strength
In clinical literature, variants affecting codon 218 of BEST1—specifically p.Arg218Cys—are described in pedigree and cohort studies of families with Best vitelliform macular dystrophy (BVMD), also called Best disease. BVMD typically follows an autosomal dominant inheritance pattern with variable penetrance and variable clinical expressivity. Clinically, affected individuals classically present during childhood or early adolescence with a bilateral, round, yellowish "egg-yolk" vitelliform lesion in the fovea. Over time, these lesions often progress through classic stages (pseudohypopyon, "scrambled egg," and eventual atrophic or cicatricial stages), resulting in a gradual decrease in central visual acuity while peripheral vision remains intact. Although the biological association with dominant bestrophinopathy is recognized, individual population-level evidence for this specific allele is categorized as limited due to its extreme scarcity in the general population and reliance on family-level segregation studies.
Population Frequency and Ancestry Patterns
According to global population sequencing resources such as the Genome Aggregation Database (gnomAD), the p.Arg218Cys variant is exceptionally rare across all surveyed ancestries, exhibiting an overall allele frequency below 0.00002. It is absent or observed only in solitary individuals across European, African, Asian, Latino, and other continental reference cohorts. Consequently, the vast majority of the global population carries two copies of the common reference allele (CC), while heterozygous (CT) and homozygous variant (TT) genotypes are virtually confined to specific families affected by inherited retinal dystrophies.
Practical Considerations: What You Can and Cannot Do
Genetic data regarding rs121908869 provides insight into molecular biology and hereditary retinal risk, but direct-to-consumer genotyping cannot serve as an independent diagnostic tool or replace a clinical eye evaluation. Commercial genotyping arrays can produce false positives on very rare single-nucleotide variants. If a genetic report indicates the presence of a rare variant in BEST1, standard clinical practice involves confirmatory clinical-grade sequencing (such as Sanger sequencing or a targeted inherited retinal disease gene panel) ordered by an eye care specialist or medical geneticist. Individuals experiencing changes in central vision, visual distortion (metamorphopsia), or with a known family history of juvenile macular degeneration can discuss these findings with an ophthalmologist or certified genetic counselor, who can perform comprehensive retinal imaging (such as optical coherence tomography and fundus autofluorescence) and electro-oculography (EOG).
How common is this variant?
The rs121908869 variant is exceedingly rare in the general population, with a global gnomAD allele frequency of less than 0.00002. More than 99.99% of people across all global ancestries carry the common reference CC genotype.
Frequently asked questions
What condition is associated with rs121908869?
This variant is associated with Best vitelliform macular dystrophy (BVMD), also called Best disease. BVMD is an inherited retinal condition that causes yellow fatty deposits (lipofuscin) to accumulate beneath the macula, often causing blurred or distorted central vision over time.
Does having the variant mean a person will definitely lose their sight?
No. Best vitelliform macular dystrophy exhibits variable expressivity and reduced penetrance, meaning individuals carrying the mutation may experience mild symptoms, later-onset vision changes, or occasionally remain asymptomatic throughout life. Furthermore, Best disease primarily affects fine central vision, leaving peripheral and night vision intact.
How does the BEST1 gene affect eye health?
The BEST1 gene produces a specialized protein channel called bestrophin-1, which regulates the passage of chloride ions and fluid across retinal pigment epithelial cells. When this channel cannot properly regulate fluid and waste transport, byproducts from the visual cycle accumulate into visible "egg-yolk" lesions beneath the retina.
Should raw consumer DNA test results for this variant be trusted?
Direct-to-consumer genetic tests can sometimes report false-positive results when analyzing extremely rare variants. If a consumer report flags a rare variant in BEST1, it should never be interpreted as a medical diagnosis without confirmatory clinical-grade sequencing arranged by a physician or genetic counselor.
Are there treatments available for conditions linked to BEST1?
Currently, standard management focuses on regular ophthalmic monitoring, low-vision aids, and treating secondary complications such as choroidal neovascularization if abnormal blood vessels form beneath the retina. Any management choices or clinical monitoring plans should always be coordinated directly with an eye care specialist.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908869?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BEST1
Encodes the Thr6Arg (T6R) missense change in Bestrophin 1 associated with autosomal dominant Best vitelliform macular dystrophy.
A missense alteration in bestrophin-1 linked to Best vitelliform macular dystrophy and central visual impairment.
Pathogenic missense variant in BEST1 (p.Ala146Thr) linked to autosomal dominant Best vitelliform macular dystrophy causing progressive loss of central vision.
Missense mutation in BEST1 causing classical Best vitelliform macular dystrophy type 2.
A pathogenic missense variant (p.Tyr227Asn) in BEST1 associated with Best vitelliform macular dystrophy.
Pathogenic missense variant (p.Thr6Arg) in BEST1 altering the bestrophin-1 channel causing autosomal dominant Best vitelliform macular dystrophy.